At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
- A Phase 1 Study of MQ710 in People With Solid Tumors
Full Title A First In Human Phase I, Open Label, Safety And Tolerability Study of Escalating Multiple Doses of Intratumoral MQ710, A Multi-Transgene Expressing Modified Vaccinia Virus Ankara-Based Virotherapy, Alone and in Combination with The Systemic Checkpoint Inhibitor Pembrolizumab in Solid Tumors
Purpose
In this study, researchers are finding the highest dose of MQ710 to use safely in people with certain types of advanced cancer. The people in this study have solid tumors that came back or grew even after treatment. In a later part of the study, the researchers will assess MQ710 plus another drug called pembrolizumab.
MQ710 is a type of immunotherapy. It is made to kill tumor cells directly as well as boost your own immune system to fight cancer. It is injected directly into tumors.
Who Can Join
To join this study, there are a few conditions. You must:
- Have a solid tumor cancer that came back or kept growing after at least two prior regimens of treatment.
- Have two or more tumors that are in a place where they can be injected with MQ710. Examples of tumors to be treated include squamous cell skin cancer, basal cell carcinoma, melanoma, and Merkel cell carcinoma. Other tumors to be treated include sebaceous carcinoma, Paget’s disease, Kaposi sarcoma, head and neck cancers, adnexal carcinoma, and angiosarcoma.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- This study is for people age 18 and older.
Contact
For more information and to see if you can join this study, please contact Dr. Lara Dunn’s office at 646-608-3787.
Protocol
22-278Phase
Phase I (phase 1)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT05859074ClinicalTrials.gov
- A Phase 2 Study of Lisocabtagene Maraleucel CAR T-Cell Therapy in People With Primary Central Nervous System Lymphoma
Full Title The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients
Purpose
Researchers are assessing the cellular therapy lisocabtagene maraleucel (liso-cel) in people with primary central nervous system lymphoma (PCNSL). The people in this study have PCNSL that has not yet been treated. In addition, they cannot have autologous stem cell transplantation (ASCT). During ASCT, a patient’s healthy, blood-forming cells are collected before treatment, stored, and returned after treatment with very strong chemotherapy.
Liso-cel is a form of immunotherapy made from your own white blood cells called T cells. If you take part in this study, we will collect some of your T cells. We will modify them in a lab so they can recognize and destroy your cancer cells. These genetically modified T cells are called chimeric antigen receptor (CAR) T cells. Treatments made from them are called CAR T-cell therapies.
While your liso-cel is being made, you may receive rituximab, methotrexate, and procarbazine and/or methotrexate, temozolomide, and rituximab. The purpose of this chemotherapy is to control your disease.
Before you get liso-cel, you will also have chemotherapy with fludarabine and cyclophosphamide to briefly weaken your immune system. This chemotherapy will help prepare your body for liso-cel. The treatments in this study are given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have previously untreated PCNSL.
- Not be eligible to receive ASCT.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information about this study or to see if you can join, please call Dr. Michael Scordo’s office at 646-608-3771.
Protocol
25-357Phase
Phase II (phase 2)Disease Status
Newly DiagnosedInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT07015242ClinicalTrials.gov
-
The purpose of this study is to find out how cancer treatments (chemotherapy and/or radiation therapy) affect reproductive and sexual health in people with early-onset colorectal cancer (diagnosed before age 50). Researchers will observe and track changes in hormone levels and in sexual and reproductive health in the study participants. This information will help them learn more about how cancer treatments affect reproductive and sexual health, including the ability to have children (fertility).
-
Bone scans, computed tomography (CT), and magnetic resonance imaging (MRI) are imaging tests used to assess the spread of cancer in the body and to determine whether anticancer treatments are working. Even with these tests, however, it is sometimes difficult to find exactly where the cancer is located and to determine whether it is growing or shrinking in response to treatment. This difficulty is particularly apparent in patients with advanced prostate cancer that has spread to the bones, as standard CT, MRI, as bone scans are not accurate in assessing cancer in the bones.
-
Cetuximab binds to a protein called EGFR, which is found on some types of tumor cells. This drug may help keep tumor cells from growing. Pembrolizumab helps the body's immune system attack the tumor and may interfere with tumor growth and spread.
-
Researchers want to see how well the drugs sapanisertib and serabelisib (PIKTOR) work when given together to treat endometrial cancer. The people in this study have endometrial cancer that has come back or grown after treatment. They also have genetic changes in the pathway that PIKTOR targets. These changes can cause resistance to chemotherapy drugs.
- A Phase 2 Study Assessing Treatment for Inflammation Before a Stem Cell Transplant in People with Immune and Autoinflammatory Conditions
Full Title Phase 2 Study Bridging Pre-Transplant Inflammatory Dampening for Primary Immune Regulatory Disorders (BRIDGE Trial)
Purpose
Primary immune regulatory disorder (PIRD) and autoinflammatory conditions are conditions of the immune system that can cause an unusual amount of inflammation. While a stem cell transplant is a standard treatment for people with a PIRD or autoinflammatory condition, the inflammation caused by these conditions can reduce the effectiveness of this treatment.
In this study, researchers are assessing treatment before transplant with emapalumab or fludarabine/dexamethasone in people with a PIRD and/or an autoinflammatory condition who are planning to have a stem cell transplant. Emapalumab or fludarabine/dexamethasone are drugs that may help reduce inflammation and enable people with a PIRD and/or an autoinflammatory condition to have a successful stem cell transplant. These drugs work by either directly blocking proteins that cause inflammation or inactivating immune cells that promote inflammation.
The medications used in this study are given intravenously (by vein). Participants will receive one of two study treatments before their stem cell transplant:
- Emapalumab
- Fludarabine and dexamethasone
Who Can Join
To be eligible for this study, patients must meet several requirements, including:
- Participants must have a PIRD and/or an autoinflammatory condition and be planning to have a stem cell transplant.
- Patients must have an appropriate stem cell donor.
- This study is for people of all ages.
Contact
For more information and to ask about eligibility for this study, please contact the office of Dr. Joseph Oved at 646-888-3314.
Protocol
23-040Phase
Phase II (phase 2)Disease Status
Newly DiagnosedInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT05787574ClinicalTrials.gov
-
In this study, researchers are comparing early treatment with venetoclax and obinutuzumab versus delayed treatment with these two medications in patients with newly diagnosed high-risk chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are not experiencing symptoms. Starting treatment with these drugs early (before patients have symptoms) may be more effective than delaying treatment until symptoms emerge.
-
The purpose of this study is to assess the safety and effectiveness of adding the drug evexomostat (SDX-7320) to standard eribulin chemotherapy in people with triple-negative breast cancer (TNBC) that has come back or spread despite treatment. In addition, the participants in this study have metabolic disorders such as high blood sugar and/or obesity. TNBC includes breast cancers that do not contain receptors for estrogen or progesterone and do not have the HER2 protein, so they cannot be treated with medications that target those proteins.
-
Researchers are assessing tepotinib with or without ramucirumab in people with non-small cell lung cancer (NSCLC). The people in this study have NSCLC that has metastasized (spread) or recurred (came back) after treatment. Their cancers also have a genetic change called the MET exon 14 skipping mutation.